Aerie Pharmaceuticals Stock News

The trading price of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) closed lower on Monday, November 22, closing at $9.70, -3.39% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Aniridia Treatment Market 2021 Industry Research Report help business or organization in every sphere of trade to take better decisions, to respond the toughest business questions and reduce the risk of failure. This market study analyzes the market status, size,

State Street Corp increased its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 18.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 992,007 shares of the companys stock after buying an additional 156,548 shares during the period. State Street Corp []

Nuveen Asset Management LLC trimmed its holdings in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 90.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 428,637 shares of the company’s stock after selling 3,933,308 shares during the quarter. Nuveen Asset Management LLC owned 0.91% of Aerie […]

Northern Trust Corp grew its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 6.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 480,138 shares of the companys stock after purchasing an additional 27,377 shares during the period. Northern Trust Corp owned approximately 1.02% []

Schonfeld Strategic Advisors LLC acquired a new stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 15,395 shares of the companys stock, valued at approximately $247,000. A number of other hedge funds have also added []

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f

Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japa

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an ove

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal impla

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman